- Home
- ENLV vs NRXP Comparison
ENLV vs NRXP Comparison
Compare ENLV & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENLV | NRXP |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.0M | 151.1M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ENLV | NRXP |
|---|---|---|
| Price | $1.11 | $3.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $20.00 | ★ $38.25 |
| AVG Volume (30 Days) | 275.8K | ★ 790.1K |
| Earning Date | 05-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $1.65 |
| 52 Week High | $7.64 | $5.06 |
Technical Indicators
Market Signals| Indicator | ENLV | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 30.84 | 49.32 |
| Support Level | $1.00 | $3.45 |
| Resistance Level | $1.26 | $3.62 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 10.76 | 46.67 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.